BSPED2022 Poster Presentations Pituitary and Growth 1 (6 abstracts)
The use of 6-monthly GnRH analogues in the paediatric population
Louise Apperley , Poonam Dharmaraj , Joanne Blair , Renuka Ramakrishnan , Urmi Das , Mohamed Didi , Peter Laing , Zoe Yung , Kelly Cassidy , Pauline Blundell , Charlotte Jarvis , Jennifer Parkinson & Senthil Senniappan
Alder Hey Children’s Hospital, Liverpool, United Kingdom
Background: Pubertal progression is inhibited in central precocious puberty with the use of gonadotropin releasing hormone (GnRH) analogues. They are usually given every 10 to 12 weeks via an intramuscular depot, but more recently, a 6-monthly preparation has become available for clinical use.
Aim: The aim of this project was to evaluate the efficacy and acceptability of 6-monthly triptorelin, a GnRH analogue, at a tertiary children’s hospital.
Methods: Individuals who were receiving 12-weekly triptorelin or were due to start GnRH analogue therapy were offered the 6-monthly preparation (Decapeptyl SR 22.5 mg). Clinical data was collected on the patients who have received 6-monthly triptorelin.
Results: In total, 34 patients were identified with a mean age of 7.4 years (+ 1.4SD; range: 2-9) at diagnosis. 32/34 (94%) patients were female. All patients received the medication for central precocious puberty and the triptorelin was switched from 12-weekly formulation to 6-monthly at an average age of 8.1 years (+1.6SD; range: 2-10). 61.8% of patients have received two doses of the 6-monthly medication to date, with the remaining 38.2% having had one dose. 44.1% of patients have been reviewed since commencing 6-monthly triptorelin and no progression in puberty has been noted. The injections have been tolerated well, with no side effects noted. The patient feedback has been positive with the need for less frequent injections and visits to the hospital.
Conclusion: The results have shown that over a short-term course, 6-monthly triptorelin has been well tolerated and has been effective in inhibiting pubertal progression. Long-term data is required, but these results are promising. The 6-monthly preparation has the potential to reduce the costs and the burden on limited healthcare resources.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more